Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia

Sílvia Casas, B. Nagy, Erkki Elonen, Anna Aventín, Marcelo L. Larramendy, Jorge Sierra, Tapani Ruutu, Sakari Knuutila

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Previous gene function analyses have indicated that HOXA9, DEK, CBL and CSF1R are aberrantly expressed in acute myeloid leukemia (AML). We analyzed the expression of these genes in a series of 41 adult patients with AML using quantitative real-time RT-PCR, and tested the association of the expression with the following hematologic and clinical parameters: age, FAB, immunophenotype and karyotype aberrations. A high proportion of the patients showed over- or underexpression of the analyzed genes. DEK was overexpressed in 98% of the cases, whereas CBL, CSF1R and HOXA9 were either overexpressed in 20%, 17% and 78% or underexpressed in 20%, 42% and 15% of the cases, respectively. Patients whose karyotype contained t(8;21)(q22;q22), showed lower relative expression of HOXA9 at a statistically significant level (p <0.05). Bone marrow samples without expression of CD34 antigen were associated with either overexpression of DEK or HOXA9. Furthermore, an association was found between the AML-M2 subtype and lower expression of CBL, CSF1R or HOXA9, and between the AML-M5 subtype and CBL or CSF1R overexpression.

Original languageEnglish
Pages (from-to)1935-1941
Number of pages7
JournalLeukemia and Lymphoma
Volume44
Issue number11
DOIs
Publication statusPublished - Nov 2003

Fingerprint

Acute Myeloid Leukemia
Karyotype
CD34 Antigens
Leukemia, Monocytic, Acute
Genes
Real-Time Polymerase Chain Reaction
Bone Marrow
Gene Expression

Keywords

  • Acute myeloid leukemia
  • Array-based methods
  • Gene expression
  • Quantitative real-time RT-PCR

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Casas, S., Nagy, B., Elonen, E., Aventín, A., Larramendy, M. L., Sierra, J., ... Knuutila, S. (2003). Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leukemia and Lymphoma, 44(11), 1935-1941. https://doi.org/10.1080/1042819031000119299

Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. / Casas, Sílvia; Nagy, B.; Elonen, Erkki; Aventín, Anna; Larramendy, Marcelo L.; Sierra, Jorge; Ruutu, Tapani; Knuutila, Sakari.

In: Leukemia and Lymphoma, Vol. 44, No. 11, 11.2003, p. 1935-1941.

Research output: Contribution to journalArticle

Casas, S, Nagy, B, Elonen, E, Aventín, A, Larramendy, ML, Sierra, J, Ruutu, T & Knuutila, S 2003, 'Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia', Leukemia and Lymphoma, vol. 44, no. 11, pp. 1935-1941. https://doi.org/10.1080/1042819031000119299
Casas, Sílvia ; Nagy, B. ; Elonen, Erkki ; Aventín, Anna ; Larramendy, Marcelo L. ; Sierra, Jorge ; Ruutu, Tapani ; Knuutila, Sakari. / Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. In: Leukemia and Lymphoma. 2003 ; Vol. 44, No. 11. pp. 1935-1941.
@article{6fc855a667bd4f14bb724431dd1637eb,
title = "Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia",
abstract = "Previous gene function analyses have indicated that HOXA9, DEK, CBL and CSF1R are aberrantly expressed in acute myeloid leukemia (AML). We analyzed the expression of these genes in a series of 41 adult patients with AML using quantitative real-time RT-PCR, and tested the association of the expression with the following hematologic and clinical parameters: age, FAB, immunophenotype and karyotype aberrations. A high proportion of the patients showed over- or underexpression of the analyzed genes. DEK was overexpressed in 98{\%} of the cases, whereas CBL, CSF1R and HOXA9 were either overexpressed in 20{\%}, 17{\%} and 78{\%} or underexpressed in 20{\%}, 42{\%} and 15{\%} of the cases, respectively. Patients whose karyotype contained t(8;21)(q22;q22), showed lower relative expression of HOXA9 at a statistically significant level (p <0.05). Bone marrow samples without expression of CD34 antigen were associated with either overexpression of DEK or HOXA9. Furthermore, an association was found between the AML-M2 subtype and lower expression of CBL, CSF1R or HOXA9, and between the AML-M5 subtype and CBL or CSF1R overexpression.",
keywords = "Acute myeloid leukemia, Array-based methods, Gene expression, Quantitative real-time RT-PCR",
author = "S{\'i}lvia Casas and B. Nagy and Erkki Elonen and Anna Avent{\'i}n and Larramendy, {Marcelo L.} and Jorge Sierra and Tapani Ruutu and Sakari Knuutila",
year = "2003",
month = "11",
doi = "10.1080/1042819031000119299",
language = "English",
volume = "44",
pages = "1935--1941",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia

AU - Casas, Sílvia

AU - Nagy, B.

AU - Elonen, Erkki

AU - Aventín, Anna

AU - Larramendy, Marcelo L.

AU - Sierra, Jorge

AU - Ruutu, Tapani

AU - Knuutila, Sakari

PY - 2003/11

Y1 - 2003/11

N2 - Previous gene function analyses have indicated that HOXA9, DEK, CBL and CSF1R are aberrantly expressed in acute myeloid leukemia (AML). We analyzed the expression of these genes in a series of 41 adult patients with AML using quantitative real-time RT-PCR, and tested the association of the expression with the following hematologic and clinical parameters: age, FAB, immunophenotype and karyotype aberrations. A high proportion of the patients showed over- or underexpression of the analyzed genes. DEK was overexpressed in 98% of the cases, whereas CBL, CSF1R and HOXA9 were either overexpressed in 20%, 17% and 78% or underexpressed in 20%, 42% and 15% of the cases, respectively. Patients whose karyotype contained t(8;21)(q22;q22), showed lower relative expression of HOXA9 at a statistically significant level (p <0.05). Bone marrow samples without expression of CD34 antigen were associated with either overexpression of DEK or HOXA9. Furthermore, an association was found between the AML-M2 subtype and lower expression of CBL, CSF1R or HOXA9, and between the AML-M5 subtype and CBL or CSF1R overexpression.

AB - Previous gene function analyses have indicated that HOXA9, DEK, CBL and CSF1R are aberrantly expressed in acute myeloid leukemia (AML). We analyzed the expression of these genes in a series of 41 adult patients with AML using quantitative real-time RT-PCR, and tested the association of the expression with the following hematologic and clinical parameters: age, FAB, immunophenotype and karyotype aberrations. A high proportion of the patients showed over- or underexpression of the analyzed genes. DEK was overexpressed in 98% of the cases, whereas CBL, CSF1R and HOXA9 were either overexpressed in 20%, 17% and 78% or underexpressed in 20%, 42% and 15% of the cases, respectively. Patients whose karyotype contained t(8;21)(q22;q22), showed lower relative expression of HOXA9 at a statistically significant level (p <0.05). Bone marrow samples without expression of CD34 antigen were associated with either overexpression of DEK or HOXA9. Furthermore, an association was found between the AML-M2 subtype and lower expression of CBL, CSF1R or HOXA9, and between the AML-M5 subtype and CBL or CSF1R overexpression.

KW - Acute myeloid leukemia

KW - Array-based methods

KW - Gene expression

KW - Quantitative real-time RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=0242635672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242635672&partnerID=8YFLogxK

U2 - 10.1080/1042819031000119299

DO - 10.1080/1042819031000119299

M3 - Article

C2 - 14738146

AN - SCOPUS:0242635672

VL - 44

SP - 1935

EP - 1941

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -